Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 5 of 21 for:    Talimogene laherparepvec melanoma

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

Expanded access is currently available for this treatment.
Verified February 2017 by Amgen
Information provided by (Responsible Party):
Amgen Identifier:
First received: October 17, 2014
Last updated: February 22, 2017
Last verified: February 2017
The study is a phase 3b, multicenter, open-label, single-arm study designed to provide expanded access of Talimogene Laherparepvec for the treatment of subjects with unresected stage IIIB to IVM1c melanoma. The study will also evaluate the safety and tolerability of Talimogene Laherparepvec.

Condition Intervention
Unresected Stage IIIB to IVM1c Melanoma
Drug: Talimogene Laherparepvec

Study Type: Expanded Access     What is Expanded Access?
Official Title: A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma

Resource links provided by NLM:

Further study details as provided by Amgen:

Intervention Details:
    Drug: Talimogene Laherparepvec
    Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
Detailed Description:
This is a phase 3b, multicenter, open-label, single-arm, expanded access study of talimogene laherparepvec for the treatment of subjects with unresected stage IIIB to IVM1c melanoma in select European countries. Subjects with unresected stage lllB-IVM1c melanoma who are not eligible for or cannot access ongoing talimogene laherparepvec clinical trials and who meet the eligibility criteria outlined will be considered for participation in this protocol. Eligible subjects will be treated with talimogene laherparepvec until the subject has achieved a complete response, all injectable tumors have disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression beyond 6 months of therapy, intolerance of protocol treatment, or until talimogene laherparepvec receives marketing authorization approval in Europe for the treatment of melanoma, whichever occurs first. Subjects will be followed for safety approximately 30 (+7) days after the end of treatment. Thereafter, subjects who provide consent will be followed under an ongoing separate registry protocol for the long-term survival follow-up of subjects treated with talimogene laherparepvec in clinical trials. The registry protocol will also monitor for late and long-term adverse events thought to be potentially related to talimogene laherparepvec.

Ages Eligible for Study:   18 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provide informed consent prior to initiation of any protocol-specific activities/procedures.
  2. Male or female age ≥ 18 years at the time of informed consent.
  3. Histologically confirmed diagnosis of melanoma
  4. Subject has unresected stage lllB to IVM1c melanoma regardless of prior therapy
  5. Subject who is not eligible for or cannot access ongoing talimogene laherparepvec clinical trials 6.Subject does not qualify for, or cannot access, other comparable or satisfactory alternative therapy for stage IIIB to IVM1c melanoma

7. Candidate for intralesional therapy 8. Adequate organ function. 9. ECOG performance status of 0, 1, or 2.

Exclusion Criteria:

  1. Clinically active cerebral metastases.
  2. Greater than 3 visceral metastases.
  3. Bone metastases
  4. Primary ocular or mucosal melanoma.
  5. History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other symptomatic autoimmune disease.
  6. Active herpetic skin lesions or prior complications of HSV-1 infection (eg, herpetic keratitis or encephalitis)
  7. Known to have acute or chronic active hepatitis B or C infection
  8. Known to have human immunodeficiency virus infection
  9. History of other malignancy within the past 3 years
  10. Female subject is pregnant or breast-feeding, or planning to become pregnant during protocol treatment and through 3 months after the last dose of talimogene laherparepvec
  11. Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during protocol treatment and through 3 months after the last dose of talimogene laherparepvec.
  12. Subject has known sensitivity to any of the products or components to be administered during dosing.
  13. Subject has entered this protocol previously.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02297529

Contact: Amgen Call Center 866-572-6436

Research Site
Chur, Switzerland, 7000
Research Site
Lausanne, Switzerland, 1011
Research Site
Zürich, Switzerland, 8091
Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT02297529     History of Changes
Other Study ID Numbers: 20120328
2014-002834-30 ( EudraCT Number )
Study First Received: October 17, 2014
Last Updated: February 22, 2017

Keywords provided by Amgen:
unresected, Melanoma, expanded access, EU

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on May 24, 2017